Kairos Pharma (KAPA) EBT Margin (2024 - 2025)

Kairos Pharma's (KAPA) quarterly EBT Margin came in at 3.23% in Q2 2025, down 4.13% on a QoQ basis from 3.1% in Q1 2025.

Kairos Pharma (KAPA) EBT Margin (2024 - 2025) Analysis & Trends

Kairos Pharma (KAPA) has 2 years of EBT Margin data on file, last reported at 3.23% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	139.24 Bn	131.39 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	86.01 Bn	78.02 Bn	3.93 Bn	35.61%
3	Argenx Se	65.61 Bn	60.42 Bn	1.37 Bn	35.71%
4	Moderna	56.92 Bn	51.78 Bn	52.00 Mn	-528.97%
5	BeOne Medicines	42.17 Bn	37.07 Bn	1.53 Bn	18.33%
6	Alnylam Pharmaceuticals	31.58 Bn	28.27 Bn	992.69 Mn	13.77%
7	BioNTech SE	27.77 Bn	9.38 Bn	668.28 Mn	-25.06%
8	Insmed	27.52 Bn	26.36 Bn	358.27 Mn	-2.67%
9	Royalty Pharma	27.36 Bn	26.52 Bn	-	12.09%
10	Kairos Pharma	5.52 Mn	188,650.70	-	-

Download Data